Covid-19: l'Italia dona 1,2 mln di dosi di vaccino all’Iran
Il Galliera tra i protagonisti dell'incontro tenutosi a Teheran.
4 ottobre 2021, intervento del dott. Emanuele Pontali, Direttore f.f. S.C. Malattie infettive.
"Galliera Hospital is locateci in Genoa, ltaly. lt was inaugurated in 1888. lt has a capacity of 437 beds, 12 operating theaters, over 320 specialized doctors, laboratories and "imaging" facilities operating 24 hours a day.
On May, 26th 2021 a cooperation agreement between E.O. Galliera Hospital and Atieh Hospital in Tehran was signed. Such agreement opened possibilities for effective collaboration between the two countries and the two hospitals, which had actually begun in February 2021 with a bone marrow donation coordinated by the IBMDR (ltalian Bone Marrow Donor Registry) of Galliera, in favor of an lranian child.
This agreement is expected to favor professional growth among healthcare workers and also to facilitate an exchange of organizational and managerial experiences. This new 'bridge' will allow the strengthening of scientific and technical relations between the two hospitals.
The main areas of collaboration relate to research and treatment in the fields of oncology, thalassemia and bone marrow transplantation.
In addition to these collaboration initiatives an exchange of experiences on COVID-19 management is planned during the coming weeks. lt will allow sharing of COVID-challenges and subsequent interventions in the areas of locai epidemiology and hospital re-organization; organizational changes and patient management at the Emergency Room level; clinica! management; intensive care management".
ltalian response to COVID
"ltaly was one of the most severely affected countries at the early stages of the epidemie. The country responded to challenges posed by the epidemie with a variety of interventions that gradually led to better contro I of the epidemie, lower mortality and improved care:
- Organizational: centralization of COVID patients in hospitals equipped with ID and/or pneumology wards + ICU; decentralization of (molecular) diagnosis; increase in ICU beds (unfortunately shifting staff from surgery activity); training of staff as soon as new approach/intervention/treatment was available; shift of staff to COVID wards; home diagnosis and home care (as much as possible)
- Clinical care: extension of non-invasive ventilation (NIV) to non-lCU and non-pneumology wards to accelerate recovery of patients and to prevent clinica I progression and excessive burden on ICU; increase sub-intensive care beds
- Pharmacological treatment: facilitation of access to new drugs (centrai temporary approvai; centrai procurement and distribution); participation to major international clinica I trials; support of .national clinica I trials to test innovative approaches or new pharmacological interventions
- Prevention: use of appropriate Persona I protective equipment (PPE) in health care settings; use of appropriate PPE in the community; sodai distancing; appropriate use of disinfectants in health care settings and in the community; limitations in large gatherings and in indoor recreational activities; early use of anti-SARS-COV-2 monoclonal antibodies
- Vaccination: mass vaccination campaign targeting initially those at higher risk (older people; obese, immunodeficient, etc) and HCWs, then, gradually, the rest of the population aged >12 years; now: campaign for the third dose of vaccination for targeted populations (those at higher risk and HCWs)
This has been a period of fast and urgent learning as soon as new information on how to tackle this epidemie emerged; any new Guideline was lagging behind what was being shared and published within the international community. lt was hard, but we have learnt a lot that is worth sharing with our peers. That's why we want to work together".
